Eptifibatide after clot-dissolving treatment in stroke patients seen late
Tests eptifibatide after clot-dissolving treatment in adults with ischemic stroke.
Plain-language title generated from the registry record
Registry title: Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
Key facts
- Where
- Chongqing, Ganzhou, Haikou, Ji’an, and Nanchang, ChinaSee the 6 sites
- Phase
- Phase 3
Where in China
- Xinqiao Hospital and The Second Affiliated HospitalChongqing, ChinaNo longer taking part
- Ganzhou People's HospitalGanzhou, ChinaNo longer taking part
- The First Affiliated Hospital of Gannan Medical UniversityGanzhou, ChinaNo longer taking part
- The First Affiliated Hospital of Hainan Medical UniversityHaikou, ChinaNo longer taking part
- The Affiliated Hospital of Jinggangshan UniversityJi’an, ChinaNo longer taking part
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xinqiao Hospital of Chongqing
- Trial code
- NCT07347626
- Record updated
- 16 January 2026
- Original description
This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.Read full original descriptionShow less
Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial
This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.
Inclusion: Age ≥ 18 years; Acute ischemic stroke, with the time interval from last known well to hospital presentation being 4.5 to 24 hours; NIHSS score ≥ 4 before randomization; if large or medium vessel occlusion is present, an NIHSS score ≤ 10 is also required; Presence of any of the following conditions after completion of standard intravenous thrombolysis:; No significant neurological improvement within 1 hour (defined as a change in NIHSS score ≤ 1 point from baseline); Early neurological deterioration within 1 hour of onset (defined as an increase in NIHSS score ≥ 2 points from baseline); Neurological fluctuation within 24 hours after symptom onset (defined as an increase in NIHSS score ≥ 2 points from the lowest value post-thrombolysis); Ability to receive the assigned study drug within 60 minutes after intravenous thrombolysis; Signed written informed consent obtained from the patient or their legal representative.
Exclusion: Planned endovascular therapy; Intracranial hemorrhage confirmed by CT or MRI; Pre-stroke modified Rankin Scale (mRS) score ≥ 2; Allergy to eptifibatide, other glycoprotein IIb/IIIa inhibitors, aspirin, or clopidogrel; History of non-atherosclerotic arteriopathy, including moyamoya disease, arterial dissection, or fibromuscular dysplasia; Pre-existing neurological or psychiatric disease that would preclude accurate neurological assessment; History of bleeding diathesis, severe cardiac disease, liver disease, or sepsis; Any terminal illness with life expectancy < 6 months; Presence of any definite cardioembolic source, including: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, spontaneous echo contrast in the left atrium, or ejection fraction < 30%; Renal insufficiency (glomerular filtration rate < 30 ml/min or serum creatinine > 220 μmol/L [2.5 mg/dL]); Platelet count < 100 × 10⁹/L; Known hypercoagulable state; Pregnancy or lactation; Brain tumor with mass effect on imaging (except for small meningiomas); Evidence of intracranial arteriovenous malformation or aneurysm with diameter > 5 mm on CT or MR angiography; Current participation in another clinical trial; Anticipated inability to complete follow-up.